title: In systemic sclerosis patients, bosentan is safe and effective for digital ulcer prevention and it seems to attenuate the development of pulmonary arterial hypertension.
authors.affiliation: Sapienza Department of Clinical Medicine, Clinical Immunology Unit, University of Rome, Viale dell'Università 37, 00185 Rome, Italy. edoardo.rosato@uniroma1.it.
authors.forename: Antonella
authors.initials: A
authors.lastname: Romaniello
authors.forename: Giovanna
authors.initials: G
authors.lastname: Viola
authors.forename: Felice
authors.initials: F
authors.lastname: Salsano
authors.forename: Edoardo
authors.initials: E
authors.lastname: Rosato
mesh_terms: D000077300:Bosentan; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D065627:Familial Primary Pulmonary Hypertension; D005385:Fingers; D006801:Humans; D006976:Hypertension, Pulmonary / Q000517:prevention & control*; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D012883:Skin Ulcer / Q000517:prevention & control*; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D013449:Sulfonamides; D000077300:Bosentan